DBV Technologies DBVT Expenses by function — Research and development expense

Similar metrics at other companies

GERNResearch and clinical expenses — R&D

$13M-5.1%

DNTHOther Costs — Research And Development Expense

$1.49M+25.5%

NRIXInternal research and development expenses — R&D

$57.07M+12.2%

BCRXResearch, discovery and preclinical programs — Research and Development Expense (Excluding Acquired in Process Cost)

$3.97M+30.4%

SRRKEarly Research — Research And Development Expense

$1.21M-16.8%

IRONOther Research — Research And Development Expense

$2.17M+18.2%

Questions, answered.

What is DBV Technologies's expenses by function — research and development expense?

DBV Technologies (DBVT) reported expenses by function — research and development expense of $8.5M in Q1 2026.

How has DBV Technologies's expenses by function — research and development expense changed year-over-year?

DBV Technologies's expenses by function — research and development expense increased by 84.8% year-over-year, from $4.6M to $8.5M.

What is the long-term trend for DBV Technologies's expenses by function — research and development expense?

Over 4 years (2021 to 2025), DBV Technologies's expenses by function — research and development expense has grown at a 11.7% compound annual growth rate (CAGR), from $14.6M to $22.75M.

What does expenses by function — research and development expense mean?

This metric represents the total costs incurred by the company for research and development activities, including clinical trials, laboratory testing, and the development of proprietary technology platforms. It reflects the investment intensity in the company's pipeline and its commitment to advancing therapeutic candidates through regulatory stages. Investors use this to assess the company's long-term innovation potential and the capital required to reach commercialization.